• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    MIRA Pharmaceuticals, Inc. - Common Stock (NQ:MIRA)

    1.360 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 863
    Open 1.360
    Bid (Size) 1.350 (4)
    Ask (Size) 1.360 (4)
    Prev. Close 1.360
    Today's Range 1.360 - 1.360
    52wk Range 0.7300 - 2.560
    Shares Outstanding 19,069,315
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
    Via ACCESS Newswire
    MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
    Via ACCESS Newswire

    Performance

    YTD
    +18.3%
    +18.3%
    1 Month
    -2.9%
    -2.9%
    3 Month
    +12.4%
    +12.4%
    6 Month
    +42.4%
    +42.4%
    1 Year
    +4.6%
    +4.6%

    More News

    Read More
    MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
    Via ACCESS Newswire
    Monday's after hours session: top gainers and losers
    Via Chartmill
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
    Via ACCESS Newswire
    MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
    Via ACCESS Newswire
    MIRA Pharmaceuticals' Second Ketamir-2 Manuscript Accepted for Peer-Reviewed Publication Demonstrating Superior Efficacy in Preclinical Neuropathic Pain Models Versus Ketamine, Gabapentin, or Pregabalin
    Via ACCESS Newswire
    MIRA Pharmaceuticals Reports New Topical Ketamir-2 shows comparable effects to Injected Morphine in Preclinical Pain Study
    Via ACCESS Newswire
    MIRA Pharmaceuticals Announces FDA Clearance of IND for Ketamir-2, Enabling U.S. Clinical Trials in Neuropathic Pain
    Via ACCESS Newswire
    MIRA Reports Clear Reversal of Anxiety-Related Behavior in Animal Model Using SKNY-1, an Oral Drug Candidate for Obesity and Nicotine Addiction Under Definitive Agreement for Acquisition
    Via ACCESS Newswire
    Unusual volume stocks in Monday's session
    Via Chartmill
    Which stocks have an unusual volume on Thursday?
    Via Chartmill
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    MIRA Reports Potent Inflammatory Pain Relief from Non-Psychoactive Marijuana Analog Mira-55 in Animal Model, Matching Morphine Without Opioid Risks
    Via ACCESS Newswire
    US Stocks Likely To Open Higher As Trump Announces Vietnam Trade Deal: S&P 500's Golden Cross 'Reason To Expect Better Than Average Returns,' Says Expert
    Via Benzinga
    Topics Government Stocks
    Why Datadog Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    MIRA Pharmaceuticals' Marijuana Analog Mira-55 Shows Potent Pain Relief In Preclinical Study, Stock Jumps 50% After Hours
    Via Benzinga
    Topics Cannabis
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Get insights into the top gainers and losers of Wednesday's after-hours session.
    Via Chartmill
    MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition
    Via ACCESS Newswire
    EXCLUSIVE: MIRA Pharmaceuticals' Soon To Be Acquired Weight Loss Drug Reverses Obesity Markers And Cuts Nicotine Craving In Animal Study
    Via Benzinga
    MIRA Pharmaceuticals Announces New Data Underscoring Potential of SKNY-1 - A Drug Candidate Pending Acquisition - To Disrupt Weight Loss and Smoking Cessation Markets Without CNS Side Effects
    Via ACCESS Newswire
    MIRA Pharmaceuticals' Lead Drug Candidate Ketamir-2 First Manuscript Accepted for Publication in the Peer-Reviewed Journal Frontiers in Pharmacology
    Via ACCESS Newswire
    MIRA Pharmaceuticals to Participate in BIO 2025 in Boston and Highlights Ongoing Progress Across Clinical Program
    Via ACCESS Newswire

    Frequently Asked Questions

    Is MIRA Pharmaceuticals, Inc. - Common Stock publicly traded?
    Yes, MIRA Pharmaceuticals, Inc. - Common Stock is publicly traded.
    What exchange does MIRA Pharmaceuticals, Inc. - Common Stock trade on?
    MIRA Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for MIRA Pharmaceuticals, Inc. - Common Stock?
    The ticker symbol for MIRA Pharmaceuticals, Inc. - Common Stock is MIRA on the Nasdaq Stock Market
    What is the current price of MIRA Pharmaceuticals, Inc. - Common Stock?
    The current price of MIRA Pharmaceuticals, Inc. - Common Stock is 1.360
    When was MIRA Pharmaceuticals, Inc. - Common Stock last traded?
    The last trade of MIRA Pharmaceuticals, Inc. - Common Stock was at 09/30/25 04:00 PM ET
    What is the market capitalization of MIRA Pharmaceuticals, Inc. - Common Stock?
    The market capitalization of MIRA Pharmaceuticals, Inc. - Common Stock is 25.93M
    How many shares of MIRA Pharmaceuticals, Inc. - Common Stock are outstanding?
    MIRA Pharmaceuticals, Inc. - Common Stock has 26M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.